Latest news with #DiffuseIntrinsicPontineGlioma
Yahoo
24-07-2025
- Business
- Yahoo
Targepeutics Announces Strategic Investment from Yuvaan Tiwari Foundation to Support Advancement of GB13 into Clinical Trials for DIPG
HUMMELSTOWN, Pa., July 24, 2025--(BUSINESS WIRE)--Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, is proud to announce a strategic financing round led by the Yuvaan Tiwari Foundation. This investment will directly support the advancement of GB13, Targepeutics' lead drug candidate, into clinical trials for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) — one of the deadliest pediatric brain tumors. "We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community," said Sil Lutkewitte, CEO of Targepeutics. "Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG." GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG. Preclinical data have shown promising efficacy, and the new funding will accelerate the operational steps required to initiate a first-in-human trial. The FDA's Rare Pediatric Disease Designation (RPDD) for GB13 earlier this year underscores its potential impact and makes Targepeutics eligible for a Priority Review Voucher (PRV), which could expedite regulatory review and further support clinical development. The Yuvaan Tiwari Foundation, created in memory of Yuvaan Tiwari who lost his life to Diffuse Midline Glioma (DMG) at the age of 3, is committed to accelerating breakthrough research and clinical solutions for pediatric brain cancer. "We lost our son to this disease, and we know what's at stake. This is more than an investment — it's a direct action toward changing the outlook for children with DMG," said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. "Our foundation is proud to support Targepeutics' bold and innovative treatment approach. This investment reflects our focus on advancing therapies with real potential to impact the lives of children facing this devastating disease." Targepeutics remains focused on pushing the boundaries of what's possible in pediatric oncology, and this new partnership brings it one step closer to delivering transformative care to the patients who need it most. About Targepeutics Targepeutics has an intellectual property portfolio including several issued patents and additional patents pending, focused on novel targeted oncology therapeutics and diagnostics. The company has been awarded Rare Pediatric Disease Designation for GB13 which complements the Orphan Drug Designation for malignant gliomas. The company is completing the required preclinical activities and expects to file an IND for a pediatric first-in-human clinical trial in 1st quarter of 2026. ( About Yuvaan Tiwari Foundation The Yuvaan Tiwari Foundation was established in 2021 by Parvati and Satya Tiwari to honor the legacy of their son Yuvaan (Yuvi). At age two, Yuvi was diagnosed with an aggressive and fatal brain tumor called diffuse midline glioma (DMG). Yuvi fought DMG bravely for seven months. The Yuvaan Tiwari Foundation accelerates high-impact research to find a cure for DMGs and other fatal pediatric brain cancers, while supporting patients and families along their journey. ( View source version on Contacts Sil LutkewittePresidentslutkewitte@
Business Wire
24-07-2025
- Business
- Business Wire
Targepeutics Announces Strategic Investment from Yuvaan Tiwari Foundation to Support Advancement of GB13 into Clinical Trials for DIPG
HUMMELSTOWN, Pa.--(BUSINESS WIRE)--Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, is proud to announce a strategic financing round led by the Yuvaan Tiwari Foundation. This investment will directly support the advancement of GB13, Targepeutics' lead drug candidate, into clinical trials for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) — one of the deadliest pediatric brain tumors. 'We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community,' said Sil Lutkewitte, CEO of Targepeutics. 'Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG.' GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG. Preclinical data have shown promising efficacy, and the new funding will accelerate the operational steps required to initiate a first-in-human trial. The FDA's Rare Pediatric Disease Designation (RPDD) for GB13 earlier this year underscores its potential impact and makes Targepeutics eligible for a Priority Review Voucher (PRV), which could expedite regulatory review and further support clinical development. The Yuvaan Tiwari Foundation, created in memory of Yuvaan Tiwari who lost his life to Diffuse Midline Glioma (DMG) at the age of 3, is committed to accelerating breakthrough research and clinical solutions for pediatric brain cancer. 'We lost our son to this disease, and we know what's at stake. This is more than an investment — it's a direct action toward changing the outlook for children with DMG,' said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. 'Our foundation is proud to support Targepeutics' bold and innovative treatment approach. This investment reflects our focus on advancing therapies with real potential to impact the lives of children facing this devastating disease.' Targepeutics remains focused on pushing the boundaries of what's possible in pediatric oncology, and this new partnership brings it one step closer to delivering transformative care to the patients who need it most. About Targepeutics Targepeutics has an intellectual property portfolio including several issued patents and additional patents pending, focused on novel targeted oncology therapeutics and diagnostics. The company has been awarded Rare Pediatric Disease Designation for GB13 which complements the Orphan Drug Designation for malignant gliomas. The company is completing the required preclinical activities and expects to file an IND for a pediatric first-in-human clinical trial in 1st quarter of 2026. ( About Yuvaan Tiwari Foundation The Yuvaan Tiwari Foundation was established in 2021 by Parvati and Satya Tiwari to honor the legacy of their son Yuvaan (Yuvi). At age two, Yuvi was diagnosed with an aggressive and fatal brain tumor called diffuse midline glioma (DMG). Yuvi fought DMG bravely for seven months. The Yuvaan Tiwari Foundation accelerates high-impact research to find a cure for DMGs and other fatal pediatric brain cancers, while supporting patients and families along their journey. (
Hamilton Spectator
22-07-2025
- Health
- Hamilton Spectator
25 Years of Hope for Pediatric Brain Tumour Research
Bunzl Canada's Annual Golf Event Donations Approach $2M in 2025 BURLINGTON, Ontario, July 22, 2025 (GLOBE NEWSWIRE) — Bunzl Canada recently hosted its 25th annual Ripple of Hope Golf Tournament in support of the Arthur & Sonia Labatt Brain Tumour Research Centre at Toronto's Hospital for Sick Children (SickKids). On July 8th, Bunzl Canada, its vendor partners, and its customers again gathered at Greystone Golf Club in Milton, Ontario for the much-anticipated annual event. This year's theme was proudly Canadian, complete with enthusiastically worn red and white regalia and Canadian-themed menu choices. Participants enjoyed a day of golf as they fundraised and increased awareness for Toronto SickKids' advanced pediatric brain tumour research initiatives. This year's tournament marked a powerful milestone, not only in longevity but in impact. With the support of volunteers, employees, vendor partners, and customers across its business segments, Bunzl Canada has now raised over $1.93million since the tournament's inception. This year, tournament donations surpassed $135,000. Recognized as the world's largest centre dedicated to brain tumour research, under the leadership of Dr. James Rutka and his team, the centre at SickKids has pioneered transformative advancements in the treatment of childhood brain tumours. Among these is MRI-guided focused ultrasound, a pioneering technique that enables clinicians to bypass the blood-brain barrier and deliver therapy directly, in a less invasive manner, to aggressive brain tumours such as Diffuse Intrinsic Pontine Glioma (DIPG). Since the last event, Dr. Rutka and his team have made important strides in better understanding pediatric brain tumours with the recognition that what was once thought to be a single disease, medulloblastoma, is actually four distinct subtypes. This discovery revolutionized the approach to treatment, as targeted therapy has been developed for each subtype. This advancement paves the way for more precise and effective treatments, offering renewed hope for patients and their families. 'One type of medulloblastoma requires a specific treatment which may include radiation therapy and chemotherapy, whereas another one may only require chemotherapy,' said Dr. Rutka. 'We also know that young children who get medulloblastoma usually are not eligible for radiation therapy, but the sub-classification tells us what chemotherapy drugs will be most effective depending on what subclass of medulloblastoma they have.' Watch Video: Ripple of Hope: 25 Years of Supporting Pediatric Brain Tumour Research 'Before 1950, there was no survival for a child with medulloblastoma. Essentially, it was a death sentence,' said Dr. Rutka. 'Gradually, the survival increased to approximately 70%. Since our discovery of four different types of medulloblastoma, we can now offer some children with different subclasses of blastoma 80 or 90% survival. We are now curing more children with medulloblastoma than ever before.' 'I've worked closely with Bunzl for 25 years,' said Dr. Rutka. 'It is a remarkable company to work with. It's absolutely incredible, and I want to thank them sincerely for everything they've done to support the charity golf tournament.' 'Reaching the 25th anniversary of the Ripple of Hope Golf Tournament is a meaningful moment for all of us at Bunzl Canada,' said John Howlett, Bunzl Canada's President. 'Approaching $2 million in donations reflects the incredible generosity and dedication of our valued customers, vendor partners and employees. I want to extend my heartfelt thanks to everyone who's supported this cause over the years, and to Dr. Rutka and his team at SickKids for the groundbreaking work they continue to do.' About Bunzl Canada Bunzl Canada Inc. ( ) provides the cleaning and hygiene products and equipment, food and retail packaging, safety products and industrial supplies which keep over 45,000 Canadian businesses running optimally, every day. The company brings its customers the advantage of global sourcing, product innovation and national scale combined with responsive local service and deep category expertise. Bunzl Canada Inc. is an operating company of Bunzl plc (BNZL.L), a FTSE100 company listed on the London Stock Exchange in the Support Services sector. Media Inquiries Margo Hunnisett Vice President, Marketing & Communications Bunzl Canada Inc. (905) 630-3749 A photo accompanying this announcement is available at
Yahoo
25-06-2025
- Entertainment
- Yahoo
Nicole Curtis Reveals Why Her Ex-Boyfriend Appears on New Season of ‘Rehab Addict' (Exclusive)
Nicole Curtis works alongside her ex-boyfriend Ryan Sawtelle on season 9 of Rehab Addict 'We were together a long time" and "never really stayed out of contact," she tells PEOPLE Curtis says she enlisted Sawtelle's help since he was located near a Wyoming property she was restoringNicole Curtis has help from a surprising collaborator on the new season of Rehab Addict — her ex-boyfriend Ryan Sawtelle. In the season premiere (airing June 24), Sawtelle works as a carpenter on a Wyoming property from the 1890s that the HGTV star sets out to restore after a poorly executed flip. 'We were together a long time and I was very close to his family,' Curtis tells PEOPLE, explaining why she welcomed Sawtelle on the show. 'So we never really stayed out of contact. Your lives are so enmeshed.' Curtis bought the Wyoming home on a whim online during a chaotic trip to Paris in July 2022, which she says came after a 'setback' in her life. Buoyed by an averted near-crisis after she accidentally boarded the flight without her wallet, she recalls thinking, "'I'm going to knock off all my wish lists tonight," before making the spur-of-the-moment purchase. When she got to Wyoming, she enlisted Sawtelle for the renovation project. Curtis bought the Wyoming home on a whim online during a chaotic trip to Paris in July 2022, which she says came after a 'setback' in her life. Buoyed by an averted near-crisis after she accidentally boarded the flight without her wallet, she recalls thinking, "'I'm going to knock off all my wish lists tonight," before making the spur-of-the-moment purchase. When she got to Wyoming, she enlisted Sawtelle for the renovation project. 'I didn't know anyone in Wyoming, but I knew somebody near Wyoming, and so I gave him a call,' she adds of Sawtelle. 'We just went out there together and checked out the house. It wasn't anything else. There was definitely no reconciliation or 'Maybe this was a mistake not being together.' No, no, no, .... Us going separate paths was a hundred percent the best idea that we ever had.' The former couple began dating in 2018. The following year, the home restoration expert opened up about her relationship with Sawtelle, whom she met after she began following his niece's battle with Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive brain tumor found in children, via his Instagram. 'My heart is happy and having him near me brings a calm I've never known,' Curtis told PEOPLE at the time. 'Not that it's been easy. Everyone has a great first few months rocking everything they have in common. But after six months, you start digging into the other stuff and you either grow apart or negotiate those differences and move forward. And [you] have to make a decision to focus on the fun.' Curtis, whose return to HGTV comes three years after the spinoff Rehab Addict: Lake House Rescue aired in 2022, is staying mum on whether she's currently dating anyone special. 'I keep my private life private because I think there's been some very traumatic moments in my life that weren't so private,' she says. 'Another lesson learned. I tell people all the time, if you're in my circle, then you know what's going on in my life. Other than that, I stay pretty mute about everything.' Curtis has two sons: Ethan, whom she welcomed in 1997 with her ex Steven Cimini, and Harper, born in 2015, whom she shares with ex Shane Maguire. She went through a very public years-long custody battle over Harper with Maguire and became an outspoken advocate for the rights of breastfeeding mothers. Her decision to continue to breastfeed Harper at age 3 drew criticism from some and became a point of contention in her legal fight with Maguire. The former couple reached a custody agreement in October 2018. 'Our family went through a lot over the years, and so that's definitely something that I have done my best to keep my family out of the public eye and focus on the houses,' she continues. 'That's always where we wanted that focus to be.' The season premiere of Rehab Addict airs Tuesday, June 24 on HGTV at 9 ET/PT. Read the original article on People
Yahoo
13-06-2025
- Health
- Yahoo
Brandon Marsh's RBI double
South Side boxing event aims to find cure for children's brain tumor It's just about time to get ready to rumble for a good cause on the city's South Side. Dan Letz is the owner and operator of Letz Box Chicago—a pugilistic palace in Mount Greenwood. For the last several months, he's been training a good-hearted, fleet-footed field of warriors who are fighting to help find a cure for Diffuse Intrinsic Pontine Glioma (DIPG), which is a brain tumor that can develop in the brainstem. "It's horrific. It affects mainly children," Katie Gaskin said. "It's a tumor that grows within the brain stem, specifically in the ponds, and when a child is diagnosed with this, right now, they're really only given radiation as a treatment option and usually eight to 12 months to live." Gaskin's son, Anthony, was 7 years old when he died from DIPG, just 19 months after his diagnosis. In memory of Anthony, who Gaskin described as an old soul who loved the Chicago Cubs, she started the Anthony's Avengers DIPG Foundation. Letz and Gaskin have partnered to host an event on Friday, June 13 at Saint Rita of Cascia High School in benefit of Anthony's Avengers and their mission to find a cure. Starting at 7 p.m., the St. Rita Mustang's football field will be transformed into a boxing ring under the Friday night lights of a different sort. WGN's Pat Elwood brings you the story. For more info on Anthony's Avengers and the fight to find a cure, visit their website: 3:44 Now Playing Paused Ad Playing
